Vico Therapeutics

Vico Therapeutics develops targeted antisense oligonucleotide (ASO) therapies for severe neurological disorders. Its precision approach addresses underlying genetic causes. The primary candidate, VO659, targets the CAG repeat expansion mutation in polyglutamine diseases, aiming to reduce disease-causing expressions while preserving essential protein function.

Founded in 2019 by Luc Dochez, Josh Mandel-Brehm, and Dr. Judith van Deutekom, Vico Therapeutics leveraged their extensive ASO technology expertise. Their commitment to rare neurological conditions and insight into RNA-based therapies' potential to modulate gene expression drove the company's inception, focusing on the root cause of complex disorders.

The company's treatments target patients with neurodegenerative conditions like Huntington’s disease and various spinocerebellar ataxias (SCA). Vico Therapeutics envisions its innovative allele-preferential targeting strategy providing effective, disease-modifying interventions. The company is dedicated to advancing its pipeline, aiming to improve patient outcomes through genetic intervention.

High-Level Overview

Vico Therapeutics is a clinical-stage biotechnology company headquartered in Leiden, Netherlands, specializing in RNA-modifying therapies for severe genetic neurological disorders.[1][2][3] Founded in 2019, it develops disease-modifying treatments using its VICOMER platform for antisense oligonucleotides (ASOs) that target RNA to address genetic defects, with its lead candidate VO659 in Phase 1/2 trials for Huntington's disease (HD) and spinocerebellar ataxias types 1 and 3 (SCA1 and SCA3).[1][2][3] VO659 serves patients with these polyglutamine diseases—characterized by CAG repeat expansions causing toxic protein buildup and progressive motor loss—solving the lack of disease-modifying options by selectively reducing mutant proteins while sparing normal ones.[2] The company also explores early-stage programs for Rett syndrome (MECP2 modulators) and familial Alzheimer's (PSEN1 modulators).[1]

Origin Story

Vico Therapeutics was founded in 2019 by Gail Mandel, Josh Mandel-Brehm, and Luc Dochez, who brought expertise in neuroscience, biotech entrepreneurship, and business development to tackle unmet needs in genetic neurological diseases.[1][3][4] Gail Mandel serves as co-founder, Josh Mandel-Brehm as co-founder and board member, and Luc Dochez as founder and board member; Judith van Deutekom is noted as co-founder, managing director, and CSO.[3][4] The idea emerged from advancing RNA-modulating therapies, leveraging the founders' backgrounds to create allele-preferential ASOs via the VICOMER platform, with early focus on polyglutamine disorders like HD and SCAs.[1][2] Pivotal early traction includes advancing VO659 into Phase 1/2 clinical studies, positioning Vico as a key player in Netherlands' growing biotech scene.[2][3]

Core Differentiators

• VICOMER Platform: Enables creation of ASOs that modulate or edit RNA to target genetic defects, such as CAG repeat expansions, with allele-preferential action that reduces mutant proteins without impacting normal ones—supported by strong molecular evidence from genetics and histopathology studies.[1][2]
• Lead Candidate VO659: An ASO translation inhibitor in Phase 1/2 for HD, SCA1, and SCA3, addressing root causes of these orphan diseases lacking curative therapies; potential advantages include improved safety, tolerability, and patient outcomes like better motor function.[2]
• Pipeline Focus: Early discovery programs for Rett syndrome and familial Alzheimer's, expanding beyond polyglutamines to other RNA-targetable neurological disorders.[1]
• Leadership Expertise: Founders with deep domain knowledge in neuroscience and genetic medicines, driving efficient progression from discovery to clinic in a resource-constrained biotech environment.[1][4]

Role in the Broader Tech Landscape

Vico rides the wave of RNA therapeutics expansion, particularly ASOs for neurological diseases, amid surging interest in precision genetic medicines following successes like Spinraza for SMA.[2] Timing aligns with advances in allele-specific targeting and growing recognition of polyglutamine disorders' genetic basis, fueled by market forces like orphan drug incentives and rising HD/SCA prevalence projections through 2035.[2] As a Netherlands-based firm, it contributes to the country's biotech ambitions to become a global leader by 2040, influencing the ecosystem through clinical validation of RNA modulation for brain-penetrant therapies and potential partnerships in Europe's neuro-genetics hub.[3][4]

Quick Take & Future Outlook

Vico's near-term catalysts include Phase 1/2 data readouts for VO659, which could validate its platform and attract partnerships or funding amid 2025 biotech momentum in genetic diseases.[2][4] Expanding trends like improved ASO delivery to the CNS and combination therapies with gene editing will shape its path, potentially advancing Rett and Alzheimer's programs to preclinical milestones. Its influence may grow via pre-IPO liquidity options and ecosystem contributions, solidifying Vico as a leader in RNA-based neuro-therapeutics for rare disorders—echoing its founding mission to deliver first-in-class disease modifiers.[1][4]